Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951

Moerloose, Barbara De; Suciu, Stefan; Bertrand, Yves; Mazingue, Françoise; Robert, Alain; Uyttebroeck, Anne; Yakouben, Karima; Ferster, Alice; Margueritte, Geneviève; Lutz, Patrick; Munzer, Martine; Sirvent, Nicolas; Norton, Lucília; Boutard, Patrick; Plantaz, Dominique; Millot, Frédéric; Philippet, Pierre; Baila, Liliana; Benoît, Yves; Otten, Jacques

doi:10.1182/blood-2009-10-247965

Cited by 64 publications

(67 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seventy patients diagnosed with B-ALL (2002À2006) at the pediatric [n ¼ 45, EORTC-58951 protocol (11)] and adult [n ¼ 25, GRAALL-2003 protocol (12)] haematology departments of Besançon University Hospital were evaluated at diagnosis. Fifty-nine (36 children and 23 adults) were monitored by FC at least once during follow-up.…”

Section: Patientsmentioning

confidence: 99%

“…Flow cytometry analysis was performed on leukemic bone marrow samples collected at diagnosis (n ¼ 70), and after complete remission was achieved (n ¼ 145) at different time-points during follow-up according to the mandatory protocols (11,12). Normal bone marrow samples were collected from patients without blood disease during cardiothoracic surgery (n ¼ 15).…”

Section: Bone Marrow Collection and Sample Preparationmentioning

confidence: 99%

“…Adapting the treatment intensity to the individual relapse risk is critical, and the level of minimal residual disease (MRD) has emerged as a major prognostic factor (9,10). Quantification of MRD by FC is currently under investigation in European multicenter trials (11,12), which will hopefully provide new information on its capacity to produce results comparable to a molecular approach (13). The major issue for the FC strategy is to specifically quantify neoplastic B lymphoblasts by differentiating them from their normal counterparts (called hematogones).…”

mentioning

confidence: 99%

See 2 more Smart Citations

CD304 is preferentially expressed on a subset of B‐lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry

et al. 2011

View full text Add to dashboard Cite

Minimal residual disease (MRD) has emerged as a major prognostic factor for monitoring patients with B-lineage acute lymphoblastic leukemia (B-ALL). The quantification of MRD by flow cytometry (FC) is based on the identification of a leukemia-associated phenotype (LAP). Because phenotypic switch is common during treatment, multiple LAPs must be available and used for MRD detection over time.We evaluated the potential usefulness of CD304 as a new marker for monitoring MRD. CD304 was expressed in 48% of B-ALL (24/50) with discriminative fluorescence intensity compared with CD304-negative normal B-cell precursors (n ¼ 15). The sensitivity of CD304-based MRD detection reached 10 24 , as with some of established LAPs. The stability of CD304 expression evaluated during therapy and at relapse confirms the usefulness of this marker for MRD quantification. Finally, CD304 was repeatedly expressed in patients with TEL

show abstract

Section: Patientsmentioning

confidence: 99%

Section: Bone Marrow Collection and Sample Preparationmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

CD304 is preferentially expressed on a subset of B‐lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry

et al. 2011

View full text Add to dashboard Cite

show abstract

“…For instance, among the drugs used for intensive multidrug chemotherapy to treat lymphoblastic leukemia and non-Hodgkin lymphoma, glucocorticoids are an essential component [2]. Indeed, owing to their ability to induce apoptosis in normal and neoplastic lymphoid cells, glucocorticoids are used to induce remission as well as during maintenance and continuing therapy of these malignant diseases [3].…”

Section: Introductionmentioning

confidence: 99%

Preparation and Physico-Chemical Stability of Dexamethasone Oral Suspension

Binson

Venisse

Bacle³

et al. 2017

Pharmaceutical Technology in Hospital Pharmacy

View full text Add to dashboard Cite

AbstractBackgroundDexamethasone is commonly used to treat a wide variety of diseases including oncological disorders. The aim of this study was to propose a liquid formulation of dexamethasone. Therefore we have developed and assessed the stability of a 5 mg/mL dexamethasone oral suspension.MethodsA stability-indicating analytical method, using HPLC-UV, was developed and fully validated according to well-recognized international guidelines. The dexamethasone suspension was prepared using dexamethasone acetate powder and Ora-SweetResultsThe mean dexamethasone concentration of the compounded oral suspensions was equal to 5.07±0.17 mg/mL. No colour modifications, precipitate or suspending troubles was observed throughout the storage period and the pH of the oral suspensions was decreased slightly, from 4.41±0.01 to 4.20±0.02. According to the dexamethasone content determined by HPLC-UV, whatever storage condition was used, no significant degradation of dexamethasone occurred over the 60 days of the study period.ConclusionDexamethasone oral suspension prepared according to our conditions is stable over 60 days under regular storage temperatures (at 4±2 °C or at 21±3 °C).

show abstract

“…This was concomitant with a more Osteonecrosis in childhood leukemia survivors haematologica | 2013; 98 (7) 1095 intensive use of steroids in the most recent French ALL protocols. [37][38][39][40][41] It might also reflect a larger use of unrelated donors and cord blood in the HSCT group, with its subsequent effect on the post-transplant steroid dose. Finally, we cannot exclude that diagnosis of symptomatic ON was less accurate in the early period.…”

mentioning

confidence: 99%

Symptomatic osteonecrosis in childhood leukemia survivors: prevalence, risk factors and impact on quality of life in adulthood

et al. 2013

View full text Add to dashboard Cite

Articleshaematologica | 2013; 98 (7) 1089Corticosteroid can induce osteonecrosis in children with leukemia. Few studies have been designed to assess the influence of a wide range of cumulative steroid dose on this side effect. Prevalence, risk factors of symptomatic osteonecrosis and its impact on adults' Quality of Life were assessed in 943 patients enrolled in the French "Leucémies de l'Enfant et de l'Adolescent" (LEA) cohort of childhood leukemia survivors. During each medical visit, data on previous osteonecrosis diagnosis were retrospectively collected. Patients without a history but with suggestive symptoms were investigated with magnetic resonance imaging. The total steroid dose in equivalent of prednisone was calculated for each patient and its effect on osteonecrosis occurrence was studied in multivariate models. Cumulative incidence was 1.4% after chemotherapy alone versus 6.8% after transplantation (P<0.001). A higher cumulative steroid dose, age over ten years at diagnosis, and treatment with transplantation significantly increased the risk of osteonecrosis. A higher post-transplant steroid dose and age over ten years at time of transplantation were significant factors in the transplanted group. With patients grouped according to steroid dose quartile, cumulative incidence of osteonecrosis reached 3.8% in the chemotherapy group for a dose beyond 5835 mg/m 2 and 23.8% after transplantation for a post-transplant dose higher than 2055 mg/m 2 . Mean physical composite score of Quality of Life was 44.3 in patients with osteonecrosis versus 54.8% in patients without (P<0.001). We conclude that total and post-transplant cumulative steroid dose may predict the risk of osteonecrosis, a rare late effect with a strong negative impact on physical domains of Quality of Life. Symptomatic osteonecrosis in childhood leukemia survivors: prevalence, risk factors and impact on quality of life in adulthood

show abstract

Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951

Cited by 64 publications

References 23 publications

CD304 is preferentially expressed on a subset of B‐lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry

CD304 is preferentially expressed on a subset of B‐lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry

Preparation and Physico-Chemical Stability of Dexamethasone Oral Suspension

Symptomatic osteonecrosis in childhood leukemia survivors: prevalence, risk factors and impact on quality of life in adulthood

Contact Info

Product

Resources

About